Polypid Ltd. Stock Price, News & Analysis

PolyPid Ltd. (Nasdaq: PYPD) has appointed renowned colorectal surgeon Dr. Anthony J. Senagore as its Senior Medical Director. Dr. Senagore will lead the development of PolyPid’s medical infrastructure in the U.S. and play a pivotal role in the NDA submission for D-PLEX₁₀₀, aimed at preventing surgical site infections (SSIs). His extensive experience in surgery and healthcare economics is expected to enhance the company’s mission to improve surgical outcomes. The D-PLEX₁₀₀ candidate is currently in Phase 3 clinical trials.

PolyPid (Nasdaq: PYPD) announced a presentation by CFO Dikla Czaczkes Akselbrad at The Raymond James Human Health Innovation Conference on June 23, 2021, at 9:20 am EDT. The conference aims to highlight innovations in healthcare, with PolyPid focusing on improving surgical outcomes through its proprietary PLEX technology, which enhances drug delivery. The lead candidate, D-PLEX100, is undergoing Phase 3 trials for preventing surgical site infections. The presentation will be available on the company’s Investor Relations site for 90 days following.

PolyPid Ltd. (Nasdaq: PYPD) is a biopharma company focused on enhancing surgical outcomes with controlled, extended-release therapeutics. On June 2, 2021, the company announced its executive team will present at three upcoming healthcare investor conferences: the LD Micro Invitational XI on June 10, the JMP Securities Life Sciences Conference on June 16, and the Raymond James Human Health Innovation Conference on June 21. The Raymond James presentation will be webcast live and available for 90 days on PolyPid's Investor Relations website.

PolyPid Ltd. (PYPD) announced FDA approval for a single pivotal Phase 3 study of D-PLEX100 for preventing surgical site infections (SSIs) in colorectal surgery. This decision is based on the adequate results expected from the SHIELD I trial, which has already enrolled over 200 patients. The trial aims to include a total of 616 to 900 participants across multiple centers and is set to deliver top-line results by year-end 2021. This breakthrough designation could expedite development and reduce costs significantly, addressing a major healthcare issue costing up to $10 billion annually.

PolyPid Ltd. (Nasdaq: PYPD) announced significant recruitment progress in its Phase 3 SHIELD I trial of D-PLEX100, with nearly 200 patients enrolled, a doubled recruitment rate in the last three weeks. The manufacturing facility is fully equipped to meet the first 30 months of commercial demand for D-PLEX100. Financial results reveal a net loss of $8.7 million for Q1 2021, an increase from $5.9 million in Q1 2020. Cash reserves stand at $61.4 million, expected to sustain operations into 2022. Top-line results for SHIELD I are anticipated by year-end 2021.

PolyPid Ltd. (Nasdaq: PYPD) announced it will release its first quarter 2021 financial results on May 12, 2021, before the U.S. market opens. A conference call is scheduled for 8:30 AM ET to discuss the results and business updates. PolyPid is focused on enhancing surgical outcomes through its patented PLEX technology, which offers controlled drug delivery over extended periods. Their lead candidate, D-PLEX100, is currently undergoing Phase 3 trials targeting surgical site infections.

PolyPid Ltd. (Nasdaq: PYPD) announced its participation in two major healthcare conferences. The company will present at the Raymond James 42nd Annual Institutional Investors Conference on March 3, 2021, at 8:20 AM Eastern Time, and at the Barclays Global Healthcare Conference on March 9, 2021, at 7:30 AM Eastern Time. Both events will feature one-on-one investor meetings, and webcasts will be available for replay. PolyPid focuses on improving surgical outcomes with its extended-release therapeutics.

PolyPid Ltd. (Nasdaq: PYPD) announced the enrollment of the 100th patient in its Phase 3 SHIELD I clinical trial, focused on preventing surgical site infections (SSIs) following abdominal surgery. The trial aims to enroll between 616 to 900 patients across over 60 centers globally. Top-line results are anticipated by the end of 2021. PolyPid's lead product, D-PLEX100, utilizes proprietary technology for prolonged antibiotic release, receiving Breakthrough Therapy Designation from the FDA for specific surgical procedures.

PolyPid Ltd. (Nasdaq: PYPD) reports significant updates as of February 10, 2021. The company has enrolled 100 patients in the Phase 3 trials of D-PLEX100 aimed at preventing surgical site infections (SSIs) in abdominal surgeries. D-PLEX100 has received Breakthrough Therapy Designation from the FDA specifically for elective colorectal surgery. PolyPid also announced positive preclinical data for its new OncoPLEX cancer therapy and maintains a robust financial position with $66.6 million in cash as of December 31, 2020, following a successful IPO. Top-line results from SHIELD I are anticipated by year-end 2021.